Quotables
"I watched his countenance closely, to see if he was not deranged ... and I was assured by other senators after he left the room that they had no confidence in it."
U.S. Senator Smith of Indiana ; After seeing Samuel Morse demonstrate the telegraph.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8088618 | Anti-IL 13 antibodies and uses thereof The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). Th... | 01/03/2012 |
| 8048855 | Method for suppressing graft-versus-host-disease A method for effectively suppressing GVHD, which occurs after peripheral blood stem cells allotransplantation, without causing marked side effects, and a pharmaceutical composition intended for this purpose and containing human G-CSF as an active ingredient. GVHD ca... | 11/01/2011 |
| 7537932 | Antibodies that bind purified mammalian FLT3 ligands Flt3 ligand from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said ligand. Methods of using said reagents and diagnostic kits are also provided. ... | 05/26/2009 |
| 7438913 | Substances and their uses Polypeptides capable of binding human IL-13 and/or of binding human IL-4 in the presence of IL-4 Rα can be used in medicine, in diagnosis and in screening for agonists/antagonist of IL-13/IL-4. One such polypeptide is shown in FIG. 1. ... | 10/21/2008 |
| 7425421 | Method for the enumeration of micronucleated erythrocyte populations while distinguishing platelets and/or platelet-associated aggregates A method for the enumeration of micronucleated erythrocyte populations while distinguishing platelet and platelet-associated aggregates involves the use of a first fluorescent labeled antibody having binding specificity for a surface marker for reticulocytes, a seco... | 09/16/2008 |
| 7411050 | Monoclonal blocking antibody to human RANKL Disclosed herein are kits for detecting RANKL protein or nucleic acids, the kits comprising isolated human RANKL polypeptides, RANKL nucleic acids and/or antibodies specific for RANKL. ... | 08/12/2008 |
| 7410781 | IL-4/IL-13 specific polypeptides and therapeutic uses thereof Polypeptides and multimeric polypeptides capable of binding interleukin-4 (IL-4) and interluekin-13 (IL-13) which are useful therapeutically in methods of treating IL-4 and IL-13-related conditions or diseases. ... | 08/12/2008 |
| 7393684 | Immunoconjugates of anti-IL-20 antibodies and hybridoma cell lines expressing anti-IL-20 antibodies The present invention relates to blocking the activity of IL-20 polypeptide molecules. IL-20 is a cytokine that is involved in inflammatory processes and human disease. IL-20RA/IL-20RB is a common receptor for IL-20. The present invention includes anti-IL-20 antibod... | 07/01/2008 |
| 7342110 | Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same The present invention relates to antibodies that bind CD33. More particularly, the invention relates to anti-CD33 antibodies, fragments and homologues of these antibodies, humanized and resurfaced versions of these antibodies, functional equivalents and improved ver... | 03/11/2008 |
| 7341870 | Dendritic cell line The invention relates to plasmacytoid dendritic human cell lines and methods for producing the cell lines. More specifically, the invention relates to the plasmacytoid dendritic human cell line called GEN2.2, which is deposited in the CNCM under number CNCM 1-2938 a... | 03/11/2008 |
| 7326569 | Hybrid cells producing monoclonal anti-CD14 antibodies This invention provides hybridoma cell lines producing monoclonal antibodies which inhibit CD14 mediated cell activation. Monoclonal antibodies produced by these cell lines also are provided. The antibodies are useful for the detection of the presence of cell surfac... | 02/05/2008 |
| 7314722 | Cytostatin II antibodies and methods The invention relates to cytostatin II growth modulatory polypeptides, polynucleotides encoding the polypeptides, methods for producing the polypeptides, in particular by expressing the polynucleotides, and agonists and antagonists of the polypeptides. The invention... | 01/01/2008 |
| 7309780 | Antibodies to natural killer cell activating factor II The invention relates to NKAF II polypeptides, polynucleotides encoding the polypeptides, methods for producing the polypeptides, in particular by expressing the polynucleotides, and agonists and antagonists of the polypeptides. The invention further relates to meth... | 12/18/2007 |
| 7294481 | Method for producing recombinant proteins A method for producing recombinant proteins, preferably fusion proteins comprising an Fc portion of an immunoglobulin molecule, more preferably fusion proteins comprising an extracellular domain of a tumor necrosis factor receptor fused to the Fc portion of an immun... | 11/13/2007 |
| 7288250 | Monoclonal antibodies against HMGB1 In various embodiments, the present invention is drawn to antibodies or antigen-binding fragments thereof that bind to a vertebrate high mobility group box (HMGB) polypeptide, methods of detecting and/or identifying an agent that binds to an HMGB polypeptide, method... | 10/30/2007 |
| 7250493 | FC fusion proteins of human erythropoietin with increased biological activities Fc fusion proteins of human EPO with increased biological activities relative to rHuEPO on a molar basis are disclosed. The HuEPO-L-vFc fusion protein comprises HuEPO, a flexible peptide linker of about 20 or fewer amino acids, and a human IgG Fc variant. The Fc var... | 07/31/2007 |
| 7244823 | TNF-alpha variants proteins for the treatment of TNF-alpha related disorders The invention relates to novel proteins with TNF-alpha antagonist activity and nucleic acids encoding these proteins. The invention further relates to the use of the novel proteins in the treatment of TNF-alpha related disorders. ... | 07/17/2007 |
| 7227003 | Anti-TNF antibody fragments Anti-TNF antibodies and anti-TNF peptides, specific for tumor necrosis factor (TNF) are useful for in vivo diagnosis and therapy of a number of TNF-mediated pathologies and conditions, as well as polynucleotides coding for anti-TNF murine and chimeric antibodies, pe... | 06/05/2007 |
| 7214532 | Methods for identifying human cell lines useful for endogenous gene activation, isolated human cell lines identified thereby, and uses thereof The invention concerns human cells which, due to an activation of the endogenous human EPO gene, are able to produce EPO in an adequate quantity and purity to enable a cost-effective production of human EPO as a pharmaceutical preparation. Furthermore the invention ... | 05/08/2007 |
| 7214658 | Method of delivering a TNF antagonist to the brain of a human by perispinal administration without direct intrathecal injection The present invention provides specific methods of using and administering etanercept to improve cognitive function in a human, for both the treatment and prevention of cognitive impairment, or, alternatively, to enhance cognitive function including Alzheimer's Dise... | 05/08/2007 |
| RE39548 | Interleukin-5 specific recombinant antibodies An effective anti-IL-5 recombinant antibody molecule comprising heavy and/or light chain antigen-binding residues from a donor antibody. ... | 04/03/2007 |
| 7186529 | Preparation of erythropoietin by endogenous gene activation The invention relates to human cells which are capable, on the basis of an activation of the endogenous human EPO gene, of producing EPO in a sufficient amount and purity to make possible a cost-effective production of human EPO as a pharmaceutical preparation. The ... | 03/06/2007 |
| 7183108 | Selection and uses of lactic acid bacteria strains modulating non-specific immunity The invention concerns lactic acid bacteria strains capable of regulating the production of NO and inflammatory cytokines by enterocytes, depending on the inflammatory condition of said enterocytes. The strains can also be incorporated in food supplements such as fe... | 02/27/2007 |
| 7179893 | Recombinant anti-TNF-α antibodies Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, as well as polynucleotides coding for murine and c... | 02/20/2007 |
| 7144987 | Protein based tumor necrosis factor-receptor variants for the treatment of TNF related disorders The invention relates to novel proteins with TNF-receptor antagonist activity and nucleic acids encoding these proteins. The invention further relates to TNF-receptor proteins with reduced immunogenicity and the use of these novel proteins in the treatment of TNF re... | 12/05/2006 |
| 7138500 | Antibodies to human 4-1BB Novel 4-1BB ligand (4-1BB-L) polypeptides and a human cell surface receptor designated 4-1BB that binds 4-1BB-L are provided. Isolated 4-1BB-L-encoding and human 4-1BB-encoding DNA sequences, recombinant expression vectors comprising the isolated DNA sequences, and ... | 11/21/2006 |
| 7122639 | Chemokine alpha-2 antibodies Human chemokine Alpha-2-polypeptides and DNA (RNA) encoding such chemotactic cytokines and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are method for utilizing such chemotactic cytokines for the treatment of leu... | 10/17/2006 |
| 7101974 | TNF-αvariants The invention relates to novel proteins with TNF-α antagonist activity and nucleic acids encoding these proteins. The invention further relates to the use of the novel proteins in the treatment of TNF-α related disorders, such as rheumatoid arthritis. ... | 09/05/2006 |
| 7087726 | Anti-interferon-α antibodies The present invention relates generally to the generation and characterization of neutralizing anti-IFN-α monoclonal antibodies with broad reactivity against various IFN-α subtypes. The invention further relates to the use of such anti-IFN-α antibodies in the dia... | 08/08/2006 |
| 7060800 | Antibodies binding the TNF related protein, TNF-X Nucleic acids encoding mammalian, e.g., primate or rodent, genes, purified proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are provided. | 06/13/2006 |
| 7045301 | Endothelial-monocyte activating polypeptide III antibodies A human EMAP III polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for preventing and/or treating neoplasia. Diagnostic... | 05/16/2006 |
| 7030226 | Fc fusion proteins of human erythropoietin with increased biological activities Fc fusion proteins of human EPO with increased biological activities relative to rHuEPO on a molar basis are disclosed. The HuEPO-L-vFc fusion protein comprises HuEPO, a flexible peptide linker of about 20 or fewer amino acids, and a human IgG Fc variant. The Fc var... | 04/18/2006 |
| 7026132 | Method of monitoring the effect of Cathepsin S inhibitors The present invention relates to a method for monitoring the effect of in vivo administration of Cathepsin S inhibitors by measuring accumulation of an intermediate degradation product of invariant chain (Ii), in particular the p10 Ii fragment, in blood of dosed sub... | 04/11/2006 |
| 7022521 | Methods and compositions for treating platelet-related disorders using MPL pathway inhibitory agents The invention relates to the treatment of subjects for the purpose inhibiting vaso-occlusive events, including thrombosis and embolism, by administering agents which reduce the number of circulating platelets to low or below normal levels. Methods and pharmaceutical... | 04/04/2006 |
| 6982082 | Gene therapy by cell specific targeting This invention is directed to a modified cyclosporin A and to a modified, genetically engineered version of its receptor, cyclophilin. This invention is further directed to a method for treating host versus graft disease following blood marrow transplantation by tra... | 01/03/2006 |
| 6979550 | Method for diagnosis of, and determination of susceptibility to bovine mastitis The present invention discloses a method for detection and prediction of mastitis. The method comprises the steps of determining the values of mastitis indicators and comparing the values with predetermined standards, wherein deviation from the standards provides a ... | 12/27/2005 |
| 6960472 | Monoclonal antibodies against N-Terminus proBNP Monoclonal antibodies having high affinity for N-terminus pro brain natriuretic peptide (NT-proBNP) are described. The monoclonal antibodies are prepared against a synthetic peptide having the Sequence ID No. 1. Specifically, the monoclonal antibodies described are ... | 11/01/2005 |
| 6955885 | Human stanniocalcin-alpha A human stanniocalcin-alpha polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for the regulation of electrolyte imbalan... | 10/18/2005 |
| 6921644 | Follistatin-3 The present invention relates to a novel follistatin-3 protein which is a member of the family of inhibin-related proteins. In particular, isolated nucleic acid molecules are provided encoding the human follistatin-3 protein. Follistatin-3 polypeptides are also prov... | 07/26/2005 |
| 6916628 | Method for the measurement of soluble CD14 proteins separately The present invention provides a method for qualitative determination of low molecular weight soluble CD14 proteins separately. The present invention also provides antibodies specific to high molecular weight soluble CD14 proteins. Further, the present invention pro... | 07/12/2005 |
